Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.79 Consensus Target Price from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $92.79.

A number of research analysts have commented on the company. Wedbush reaffirmed a "neutral" rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Canaccord Genuity Group upped their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. upped their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th.

Ultragenyx Pharmaceutical Stock Up 1.0 %

Shares of NASDAQ:RARE traded up $0.37 during midday trading on Friday, hitting $37.68. The stock had a trading volume of 161,937 shares, compared to its average volume of 811,350. The business's 50-day simple moving average is $38.00 and its 200-day simple moving average is $43.88. Ultragenyx Pharmaceutical has a 12 month low of $29.59 and a 12 month high of $60.37. The company has a market cap of $3.54 billion, a P/E ratio of -5.95 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Howard Horn sold 1,785 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock valued at $5,256,268 over the last ninety days. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its position in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after acquiring an additional 76,150 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after acquiring an additional 294 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock worth $87,296,000 after acquiring an additional 65,623 shares during the period. KBC Group NV grew its position in shares of Ultragenyx Pharmaceutical by 2,275.8% in the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock valued at $2,567,000 after purchasing an additional 58,442 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Ultragenyx Pharmaceutical by 8.9% during the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock valued at $1,658,000 after purchasing an additional 3,246 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.